Want to see AU:MSX full AI Analyst Report?
Neuroscientific Biopharmaceuticals Ltd. (MSX) Ratios
Neuroscientific Biopharmaceuticals Ltd. Ratios
AU:MSX's free cash flow for Q4 2026 was $-1.87M. For the 2026 fiscal year, AU:MSX's free cash flow was increased by $0.00 and operating cash flow was $-1.87M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.27 | 49.56 | 58.87 | 8.39 | 3.34 |
| Quick Ratio | 14.27 | 49.56 | 58.87 | 8.39 | 3.34 |
| Cash Ratio | 7.82 | 48.69 | 57.82 | 8.22 | 3.25 |
| Solvency Ratio | -8.83 | -11.75 | 4.85 | -1.69 | -4.68 |
| Operating Cash Flow Ratio | -7.75 | -6.31 | 0.52 | -3.86 | -3.13 |
| Short-Term Operating Cash Flow Coverage | -53.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 4.42M | $ 7.25M | $ 4.96M | $ 4.41M | $ 5.18M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.03 | 1.01 | 1.02 | 1.13 | 1.40 |
| Debt Service Coverage Ratio | -63.89 | 0.00 | 0.00 | -213.56 | 0.00 |
| Interest Coverage Ratio | -1391.44 | 0.00 | 0.00 | -1293.70 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.68 | 3.79 | 2.76 | 0.82 | 0.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | -4.13% | -1.17% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | -85.36% | -121.58% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | -81.20% | -120.41% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | -93.00% | -123.65% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | -85.36% | -121.58% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 14.66% | -21.58% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 14.66% | -21.58% | 0.00% |
| Net Income Per EBT | 92.10% | 100.00% | -17.17% | 17.75% | 100.00% |
| EBT Per EBIT | 99.76% | 96.26% | 91.78% | 98.33% | 99.34% |
| Return on Assets (ROA) | -30.91% | -10.88% | 5.96% | -20.20% | -134.87% |
| Return on Equity (ROE) | -31.69% | -10.98% | 6.06% | -22.77% | -189.05% |
| Return on Capital Employed (ROCE) | -34.40% | -11.40% | -38.45% | -130.48% | -190.30% |
| Return on Invested Capital (ROIC) | -31.58% | -11.40% | 6.60% | -23.16% | -190.30% |
| Return on Tangible Assets | -95.52% | -24.95% | 6.42% | -21.30% | -140.73% |
| Earnings Yield | -23.58% | -14.48% | 5.50% | -9.31% | -40.41% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 40.60 | 113.95 | 0.00 |
| Payables Turnover | 5.13 | 0.00 | 1.08 | 0.10 | 0.03 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 342.44 | 563.42 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.41 | 0.94 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.47 | 1.03 | 0.00 |
| Cash Conversion Cycle | -71.17 | -115152.48 | -330.40 | -3690.73 | -12178.87 |
| Days of Sales Outstanding | 0.00 | 0.00 | 8.99 | 3.20 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 71.17 | 115152.48 | 339.39 | 3693.94 | 12178.87 |
| Operating Cycle | 0.00 | 0.00 | 8.99 | 3.20 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | 0.00 | -0.02 | -0.05 |
| Free Cash Flow Per Share | 0.00 | -0.01 | 0.00 | -0.02 | -0.05 |
| Dividend Paid and CapEx Coverage Ratio | -1.00 | 0.00 | 24.38 | 0.00 | -1795.74 |
| Capital Expenditure Coverage Ratio | -1.00 | 0.00 | 24.38 | 0.00 | -1795.74 |
| Operating Cash Flow Coverage Ratio | -29.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.02 | -0.47 | 0.00 |
| Free Cash Flow Yield | 0.00% | -7.39% | 0.72% | -20.08% | -26.90% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.24 | -6.90 | 18.18 | -10.74 | -2.47 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 2.67 | 2.32 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.34 | 0.76 | 1.10 | 2.45 | 4.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.00 | -13.54 | 138.92 | -4.98 | -3.72 |
| Price-to-Operating Cash Flow Ratio | -7.64 | -13.54 | 133.22 | -4.98 | -3.72 |
| Price-to-Earnings Growth (PEG) Ratio | -0.41 | 0.01 | -0.14 | 0.12 | -0.01 |
| Enterprise Value Multiple | -4.66 | -2.86 | -0.52 | -1.10 | -1.79 |
| Enterprise Value | 17.36M | 5.48M | 940.58K | 6.57M | 18.61M |
| EV to EBITDA | -4.66 | -2.86 | -0.52 | -1.10 | -1.79 |
| EV to Sales | 0.00 | 0.00 | 0.43 | 1.33 | 0.00 |
| EV to Free Cash Flow | 0.00 | -5.82 | 22.17 | -2.85 | -2.68 |
| EV to Operating Cash Flow | -6.66 | -5.82 | 21.26 | -2.85 | -2.68 |
| Tangible Book Value Per Share | 0.01 | 0.05 | 0.03 | 0.03 | 0.04 |
| Shareholders’ Equity Per Share | 0.04 | 0.11 | 0.04 | 0.03 | 0.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.08 | 0.00 | 1.17 | 0.82 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.02 | 0.03 | 0.00 |
| Net Income Per Share | -0.01 | -0.01 | 0.00 | -0.01 | -0.07 |
| Tax Burden | 0.92 | 1.00 | -0.17 | 0.18 | 1.00 |
| Interest Burden | 1.00 | 0.92 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.22 | 0.81 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.30 | 0.36 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 |
| Income Quality | 0.56 | 0.51 | 0.00 | 2.16 | 0.67 |
Currency in AUD